Factors predicting the development of urinary tract disorders in prostatic hyperplasia in elderly men


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review article presents information from foreign and domestic authors on the relevance of studying the incidence of men with bening prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Complex urodynamic studies (CUDS) remains the most informative test of the degree of expression of LUTS and bladder outlet obstruction (ВОО) caused by BPH. The difficulty in interpreting the results, the invasiveness and inaccessibility of CUDS in the routine practice of most medical institutions makes it necessary to perform relatively simpler and more accessible methods of research, which do not always objectively reflect the degree of urinary incontinence in older men. This fact causes a large number of complications and adverse outcomes of surgical treatment with the rapid development of BPH and obstructive symptoms. Taking into account the results of world research, the study of the urine proteome and urinary exosomes will improve the quality of diagnosis in patients with BPH and help in assessing the prognosis of the development of the disease.

Full Text

Restricted Access

About the authors

V. A Dudarev

FGBOU VO «Chita State Medical University»

Email: dudarevv94@gmail.com
assistant at the Department of Faculty Surgery with the course of Urology

V. Yu Startsev

FGBOU VO «Saint-Petersburg State Pediatric Medical University»

Email: vlad_startsev@mail.ru
Dr.Med.Sci., professor at the Department of Oncology, Pediatric Oncology and Radiation Therapy

References

  1. Temml C., Brossner C., Schatzl G., Ponholzer A., ICnoepp L., Madersbacher S. Prostate Study Group of the Austrian Society of Urology. The natural history of lower urinary tract symptoms over five years. Eur Urol. 2003;43(4):374-380.
  2. Skolarikos A., Thorpe A.C., Neal D.E. Lower urinary tract symptoms and benign prostatic hyperplasia. Minerva urologica e nefrologica. 2004;56(2):109-122.
  3. Vos T. et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163-2196. doi: 10.1016/S0140-6736(12)61729-2].
  4. Homma Y., Gotoh M., Yokoyama O., Masumori N., Kawauchi A., Yamanishi T., Ishizuka O., Seki N., Kamoto T., Nagai A., Ozono S. Outline of JUA clinical guidelines for benign prostatic hyperplasia. Int J. Urol. 2011;18(11):741- 756.
  5. Eapen R.S., Radomski S.B. Review of the epidemiology of overactive bladder. Res Rep Urol. 2016;8:71-76.
  6. Groves H.K., Chang D., Palazzi K., Cohen S., Parsons J.K. The incidence of acute urinary retention secondary to BPH is increasing among California men. Prostate Cancer Prostatic Dis. 2013;16(3):260-265.
  7. McVary K.T., Roehrborn C.G., Avins A.L., Barry M.J., Bruskewitz R.C., Donnell R.F., Foster H.E. Jr., Gonzalez C.M., Kaplan S.A., Penson D.F., Ulchaker J.C., Wei J.T. Update on AUA guideline on the management of benign prostatic hyperplasia. J. Urol. 2011;185(5):1793-1803.
  8. Stroup S.P., Palazzi-Churas K., Kopp R.P., Parsons J.K. Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008. BJU Int. 2012;109(1):84-87.
  9. Loeb S., Kettermann A., Carter H.B., Ferrucci L., Metter E.J., Walsh P.C. Prostate volume changes over time: Results from the Baltimore Longitudinal Study of Aging. J. Urol. 2009; 182(4):1458-1462.
  10. McVary K.T., Roehrborn C.G., Avins A.L., Barry M.J., Bruskewitz R.C., Donnell R.F., Foster H.E. Jr., Gonzalez C.M., Kaplan S.A., Penson D.F., Ulchaker J.C., Wei J.T. Update on AUA guideline on the management of benign prostatic hyperplasia. J. Urol. 2011; 185(5):1793-1803.
  11. Лопаткин Н.А. Урология. Национальное руководство. М.: ГЭОТАР-Медиа, 2009. 1024 с.
  12. Ko Y.H., Chae J.Y., Jeong S.M., Kang J.I., Ahn H.J., Kim H.W., Kang S.G., Jang H.A., Cheon J., Kim J.J., Lee J.G. Clinical implications of residual urine in Korean benign prostatic hyperplasia (BPH) patients: a prognostic factor for BPH-related clinical events. Int Neurourol J. 2010;14(4):238-244.
  13. Амдий Р.Э., Гиоргобиани Т.Г. Диагностика инфравезикальной обструкции на основе комплексной оценки результатов обследования больных доброкачественной гиперплазией предстательной железы. Урологические ведомости. 2012;3:8-13
  14. Аляев Ю.Г., Локшин К.Л., Гаджиева З.К., Тангриберганов М.Р. Оценка уродинамических показателей у больных доброкачественной гиперплазией предстательной железы. Медицинский вестник Башкортостана. 2011(6):2:12-14
  15. Malde S., Nambiar A.K., Umbach R., Lam T.B., Bach T., Bachmann A., Drake M.J., Gacci M., Gratzke C., Madersbacher S., Mamoulakis C., Tikkinen K.A., Gravas S. Systematic review of the performance of noninvasive tests in diagnosing bladder outlet obstruction in men with lower urinary tract symptoms. Eur Urol. 71(3):391-402.
  16. Шкодкин С.В., Идашкин Ю.Б., Шадеркин И.А., Шадеркина В.А., Полищук А.В., Чирков С.В. Трансуретральная резекция доброкачественной гиперплазии предстательной железы и нарушения микции. Экспериментальная и клиническая урология. 2017:2:68-72
  17. Аляев Ю.Г., Винаров А.З., Локшин К.Л., Спивак Л.Г. Выбор метода лечения больных гиперплазией предстательной железы. М: Клиника урологии ММА им. И.М. Сеченова. 2005. 176 с.
  18. Вишневский Е.Л., Лоран О.Б., Пушкарь Д.Ю., Петров С.Б. Обструктивная ноктурия. М.: АНМИ. 2007. 162 с.
  19. Гаджиева З.К. Нарушения мочеиспускания: руководство. Под ред. Аляева Ю.Г. М.: ГЭОТАР Медиа. 2010; 176 с.
  20. Гаджиева З.К. Уродинамические исследования в диагностике и лечении нарушений мочеиспускания: автореф. дис. д.м.н. М., 2009; 319 с.
  21. Кривобородов Г.Г., Ефремов Н.С., Болотов А.Г. Интравезикальная простатическая протрузия в диагностике инфравезикальной обструкции мужчин с доброкачественной гиперплазией предстательной железы. Урология. 2017;2:105-109
  22. Lee L.S., Sim H.G., Lim K.B., Wang D., Foo K.T. Intravesical prostatic protrusion predicts clinical progression of benign prostatic enlargement in patients receiving medical treatment. Int J. Urol. 2010;17:69-74.
  23. Cumpanas A.A., Botoca M., Minciu R., Bucuras V. Intravesical prostatic protrusion can bea predicting factor for the treat men tout come in patients with lower urinary tract symptoms duet o benign prostatic obstruction treated with tamsulosin. Urology. 2013;81:859-863.
  24. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2014:15.
  25. Mangera А., Osman N.I., Chapple C.R. Assessment of BPH/BOO. Indian J. Urol. 2014;30(2):177-180.
  26. Bartsch G., Fitzpatrick J.M., Schalken J.A., Isaacs J., Nordling J., Roehrborn C.G. Consensus statement: The role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia. BJU Int. 2004;93(1):27-29.
  27. Cho K.J., Koh J.S., Choi J., Kim J.C. Changes in adenosine triphosphate and nitric oxide in the urothelium of patients with benign prostatic hyperplasia and detrusor underactivity. J. Urol. 2017;198(6):1392-1396.
  28. Захарова Н.Б., Пастушкова Л.Х., Ларина И.М., Каширина Д.Н., Лях Р.Н., Попков В.М. Значение протеомного состава мочи при заболеваниях мочевыводящих путей (обзор литературы) Экспериментальная и клиническая урология. 2017;1:22-29
  29. Ozer J.S., Dieterle F., Troth S., Perentes E. et al. A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nature Biotechnology. 2010;28(5):486-494.
  30. Ma J., Gharaee-Kermani M., Kunju L., Hollingsworth J.M., Adler J., Arruda E.M., Macoska J.A. Prostatic fibrosis is associated with lower urinary tract symptoms. J. Urol. 2012;188(4):1375-1381.
  31. Rodriguez-Nieves J.A., Macoska J.A. Prostatic fibrosis, lower urinary tract symptoms, and BPH. Nat Rev Urol. 2013;10(9):546-550.
  32. Bauman T.M., Nicholson T.M., Abler L.L., Eliceiri K.W., Huang W., Vezina C.M., Ricke W.A. Characterization of fibrillar collagens and extracellular matrix of glandular benign prostatic hyperplasia nodules. PLoS One. 2014;9(10):e109102.
  33. Bygd H.C., Akilbekova D., Munoz A., Forsmark K.D., Bratlie K.M. Poly-L-arginine based materials as instructive substrates for fibroblast synthesis of collagen. Biomaterials. 2015;63:47-57.
  34. Hao L., Greer T., Page D., Shi Y., Vezina C.M., Macoska J.A., Marker P.C., Bjorling D.E., Bushman W., Ricke W.A., Li L. In-Depth Characterization and Validation of Human Urine Metabolomes Reveal Novel Metabolic Signatures of Lower Urinary Tract Symptoms. 2016;6:30869.
  35. Cho K.J., Koh J.S., Choi J., Kim J.C. Changes in adenosine triphosphate and nitric oxide in the urothelium of patients with benign prostatic hyperplasia and detrusor underactivity. J. Urol. 2017;198(6):1392-1396.
  36. Gheinani A.H., Kiss B., Moltzahn F., Keller I., Bruggmann R., Rehrauer H., Fournier K.A., Burkhard F.C., Monastyrskaya K. Characterization of miRNA-regulated networks, hubs of signaling, and biomarkers in obstruction-induced bladder dysfunction. JCI Insight. 2017;2(2):e89560.
  37. Кирпатовский В.И., Мудрая И.С., Федяков Р.П., Голованов С.А., Дрожжева В.В., Черников Д.Ю., Елисеев Д.Э., Надточий О.Н., Сыромятникова Е.В. Ферментурия как маркер повреждения мочевого пузыря при острой задержке мочи. Экспериментальная и клиническая урология. 2012;1:20-23
  38. Franzen C.A., Blackwell R.H., Foreman K.E., Kuo P.C., Flanigan R.C., Gupta G.N. Urinary exosomes: the potential for biomarker utility, intercellular signaling and therapeutics in urological malignancy. J. Urol. 2016;195(5):1331-1339.
  39. Silvers C.R., Miyamoto H., Messing E.M., Netto G.J., Lee Y.F. Characterization of urinary extracellular vesicle proteins in muscle-invasive bladder cancer. Oncotarget. 2017;8(53):91199-91208.
  40. Li X., Jiang T., Liu F., Shao X., Xu Y., Sheng W., Sun W. Clinical evaluation of urine prostatic exosomal protein in the diagnosis of chronic prostatitis. UrolInt. 2018;100(1):112-118.
  41. Fujita K., Kume H., Matsuzaki K., Kawashima A., Ujike T., Nagahara A., Uemura M., Miyagawa Y., Tomonaga T., Nonomura N. Proteomic analysis of urinary extracellular vesicles from high Gleason score prostate cancer. Sci Rep. 2017;7:42961.
  42. Williams K., Colangelo C., Hou L., Chung L., Belcher J., Abbott T., Hall I., Zhao H., Cantley L., Parikh C. Use of a Targeted Urine Proteome Assay (TUPA) to Identify Protein Biomarkers of Delayed Recovery After Kidney Transplant. Proteomics Clin Appl. 2017;11(7-8): 10.1002/prca.20160013.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies